CIK 0000072444
- Accelerated filer
- Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 591212264
- Phone
- +1 650-550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-02-13 | Tucker Sean Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +4,027 | 4,027 | ||
| 2018-02-13 | Tucker Sean Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +1,006 | 1,006 | ||
| 2018-02-13 | Tucker Sean Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +3,020 | 3,020 | ||
| 2018-02-13 | Tucker Sean Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +10,523 | 10,523 | ||
| 2018-02-13 | Tucker Sean Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +11,604 | 11,604 | ||
| 2018-02-13 | Tucker Sean Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +10,067 | 10,067 | ||
| 2018-02-13 | Tucker Sean Chief Scientific Officer | Grant or award · Stock Optin (right to buy) | +7,731 | 7,731 | ||
| 2018-02-13 | Tucker Sean Chief Scientific Officer | Grant or award · Stock Optin (right to buy) | +9,060 | 9,060 | ||
| 2018-02-13 | Latour Wouter President and Chief Executive | Grant or award · Stock Option (right to buy) | +6,536 | 6,536 | ||
| 2018-02-13 | Latour Wouter President and Chief Executive | Grant or award · Stock Option (right to buy) | +9,442 | 9,442 | ||
| 2018-02-13 | Latour Wouter President and Chief Executive | Grant or award · Stock Option (right to buy) | +13,256 | 13,256 | ||
| 2018-02-13 | Latour Wouter President and Chief Executive | Grant or award · Stock Option (right to buy) | +14,908 | 14,908 | ||
| 2018-02-13 | Latour Wouter President and Chief Executive | Grant or award · Stock Option (right to buy) | +18,120 | 18,120 | ||
| 2018-02-13 | Latour Wouter President and Chief Executive | Grant or award · Stock Option (right to buy) | +10,731 | 10,731 | ||
| 2018-02-13 | Latour Wouter President and Chief Executive | Grant or award · Stock Option (right to buy) | +23,651 | 23,651 | ||
| 2018-02-13 | Harland John M Chief Financial Officer | Grant or award · Stock Option (right to buy) | +9,563 | 9,563 | ||
| 2018-02-13 | Harland John M Chief Financial Officer | Grant or award · Stock Option (right to buy) | +8,255 | 8,255 | ||
| 2018-02-13 | Harland John M Chief Financial Officer | Grant or award · Stock Option (right to buy) | +4,087 | 4,087 | ||
| 2018-02-13 | Harland John M Chief Financial Officer | Grant or award · Stock Option (right to buy) | +7,047 | 7,047 | ||
| 2018-02-13 | Finney Michael J. Director | Grant or award | +228,978 | 228,978 |
Page 21 of 23 · 442 trades